Next Article in Journal
Comparative EPR Study on the Scavenging Effect of Methotrexate with the Isomers of Its Photoswitchable Derivative
Next Article in Special Issue
Current Status of Baricitinib as a Repurposed Therapy for COVID-19
Previous Article in Journal
Structure–Activity Relationship Analysis of Benzimidazoles as Emerging Anti-Inflammatory Agents: An Overview
Previous Article in Special Issue
Therapeutic Potential of Glycosyl Flavonoids as Anti-Coronaviral Agents
Opinion

COVID-19: Failure of the DisCoVeRy Clinical Trial, and Now–New Hopes?

Formerly Head of the Department of Organic Chemistry (FS), University of Mons-UMONS, 7000 Mons, Belgium
Academic Editor: Gerald Reischl
Pharmaceuticals 2021, 14(7), 664; https://0-doi-org.brum.beds.ac.uk/10.3390/ph14070664
Received: 15 June 2021 / Revised: 4 July 2021 / Accepted: 8 July 2021 / Published: 11 July 2021
(This article belongs to the Special Issue COVID-19 in Pharmaceuticals)
The DisCoVeRy clinical trial aimed at the evaluation of four treatments for patients suffering from severe to critical COVID-19: Hydroxychloroquine, eventually associated with azithromycin; the combination lopinavir/ritonavir; the combination with the addition of interferon β-1a; remdesivir. The trial was discontinued due to the lack of positive results. Meanwhile, many other potential options have been considered either to target the virus itself, the interactions with the host cells, or the cytokine storm frequently observed during the infection. Several of those options are briefly reviewed. They include vaccines, small molecules, antibodies, and stem cells. View Full-Text
Keywords: antibodies; COVID-19; cytokine storm; hydroxychloroquine; lopinavir; remdisivir; ritonavir; SARS-CoV-2; stem cells; vaccine antibodies; COVID-19; cytokine storm; hydroxychloroquine; lopinavir; remdisivir; ritonavir; SARS-CoV-2; stem cells; vaccine
Show Figures

Graphical abstract

MDPI and ACS Style

Vanden Eynde, J.J. COVID-19: Failure of the DisCoVeRy Clinical Trial, and Now–New Hopes? Pharmaceuticals 2021, 14, 664. https://0-doi-org.brum.beds.ac.uk/10.3390/ph14070664

AMA Style

Vanden Eynde JJ. COVID-19: Failure of the DisCoVeRy Clinical Trial, and Now–New Hopes? Pharmaceuticals. 2021; 14(7):664. https://0-doi-org.brum.beds.ac.uk/10.3390/ph14070664

Chicago/Turabian Style

Vanden Eynde, Jean J. 2021. "COVID-19: Failure of the DisCoVeRy Clinical Trial, and Now–New Hopes?" Pharmaceuticals 14, no. 7: 664. https://0-doi-org.brum.beds.ac.uk/10.3390/ph14070664

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop